Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection

Pre-eclampsia is the second leading cause of maternal morbidity and mortality in the United States. Infants born to affected mothers face a five-fold increase in death rate [Lain and Roberts 2002; National Heart Lung and Blood Institute 2001]. Although pre-eclampsia has been recognized by physicians for millennia, relatively little is known about its pathogenesis or prevention. Predicting its development is often extremely difficult, perhaps leading the Greeks to use the name 'eklampsis' meaning lightening. Recent studies provide novel insights into the role of the placenta in the development of pre-eclampsia and demonstrate novel markers to assist in predicting the onset of disease and potential therapeutic targets. Following an introduction which highlights the classification of hypertensive disorders of pregnancy and defines incidence and adverse outcomes of pre-eclampsia, this manuscript will discuss the role of the placenta in the pathophysiology of pre-eclampsia and recent markers that may predict its onset.

[1]  Anne B Wallis,et al.  Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. , 2008, American journal of hypertension.

[2]  B. Huppertz.  Placental Origins of Preeclampsia: Challenging the Current Hypothesis , 2008, Hypertension.

[3]  Asif Ahmed,et al.  Autoantibody From Women With Preeclampsia Induces Soluble Fms-Like Tyrosine Kinase-1 Production via Angiotensin Type 1 Receptor and Calcineurin/Nuclear Factor of Activated T-Cells Signaling , 2008, Hypertension.

[4]  Aeilko H. Zwinderman,et al.  Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis , 2008, Canadian Medical Association Journal.

[5]  K. Spencer,et al.  First‐trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes , 2008, Prenatal diagnosis.

[6]  Wenjiang J. Fu,et al.  A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[7]  L. Shulman.  First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction , 2008 .

[8]  D. Hajjar,et al.  Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury. , 2008, Hypertension.

[9]  V. Garovic,et al.  Hypertension in pregnancy: an emerging risk factor for cardiovascular disease , 2007, Nature Clinical Practice Nephrology.

[10]  U. Reddy,et al.  Review Article: Preeclampsia—A Pressing Problem: An Executive Summary of a National Institute of Child Health and Human Development Workshop , 2007, Reproductive Sciences.

[11]  Donna D. Johnson,et al.  Soluble endoglin as a second-trimester marker for preeclampsia. , 2007, American journal of obstetrics and gynecology.

[12]  S. Karumanchi,et al.  Pre-Eclampsia: Clinical Manifestations and Molecular Mechanisms , 2007, Nephron Clinical Practice.

[13]  R. Lafayette,et al.  Pathophysiology of the clinical manifestations of preeclampsia. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[14]  N. Bersinger,et al.  Serum markers for predicting pre-eclampsia. , 2007, Molecular aspects of medicine.

[15]  Asif Ahmed,et al.  Angiotensin II Induces Soluble fms-Like Tyrosine Kinase-1 Release via Calcineurin Signaling Pathway in Pregnancy , 2007, Circulation research.

[16]  A. Benigni,et al.  Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors: A Systematic Review , 2007, Obstetrics and gynecology.

[17]  S. Ramin,et al.  Angiotensin Receptors, Autoimmunity, and Preeclampsia , 2007 .

[18]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[19]  L. Poston,et al.  Vitamin C and vitamin e in pregnant women at risk for pre-eclampsia (VIP trial) : Randomized placebo-controlled trial , 2006 .

[20]  C. Lanzani,et al.  Plasma and Tissue Expression of the Long Pentraxin 3 During Normal Pregnancy and Preeclampsia , 2006, Obstetrics and gynecology.

[21]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[22]  L. Poston,et al.  Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial , 2006, The Lancet.

[23]  B. Lane,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[24]  L. Poston,et al.  A randomised controlled trial (RCT) of vitamin C and E supplementation in high risk women to prevent pre-eclampsia (the VIP trial; On behalf of the VIP trial consortium) ISRCTN 62368611 , 2006 .

[25]  I. Policlinico.  Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction , 2006 .

[26]  M. Schull,et al.  Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study , 2005, The Lancet.

[27]  R. Frydman,et al.  Selective fetocide reverses preeclampsia in discordant twins. , 2005, American journal of obstetrics and gynecology.

[28]  F. Epstein,et al.  Preeclampsia: a renal perspective. , 2005, Kidney international.

[29]  R. Gaiser,et al.  Circulating Angiogenic Factors and the Risk of Preeclampsia , 2005 .

[30]  C. Garlanda,et al.  Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. , 2005, Annual review of immunology.

[31]  J. Davison,et al.  New aspects in the pathophysiology of preeclampsia. , 2004, Journal of the American Society of Nephrology : JASN.

[32]  D. Merrill,et al.  Enhanced expression of Ang-(1-7) during pregnancy. , 2004, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[33]  R. Gonenc,et al.  Placental Protein 13 ( PP-13 ) : Effects on Cultured Trophoblasts , and Its Detection in Human Body Fluids in Normal and Pathological Pregnancies , 2004 .

[34]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[35]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[36]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[37]  Gail D Pearson,et al.  Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy , 2003, Hypertension in pregnancy.

[38]  James M. Roberts,et al.  Contemporary concepts of the pathogenesis and management of preeclampsia. , 2002, JAMA.

[39]  J. Martin,et al.  Preeclampsia: pathophysiology and practice considerations for the consulting nephrologist. , 2002, Seminars in nephrology.

[40]  H. Lother,et al.  Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness , 2001, Nature Medicine.

[41]  Jm Roberts,et al.  Pathogenesis and genetics of pre-eclampsia , 2001, The Lancet.

[42]  R. Dersimonian,et al.  Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. , 1999, JAMA.

[43]  B. Brooke,et al.  Defective angiogenesis in mice lacking endoglin. , 1999, Science.

[44]  G. Wallukat,et al.  Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. , 1999, The Journal of clinical investigation.

[45]  B. Sibai,et al.  Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. , 1998, The New England journal of medicine.

[46]  J. Cutler,et al.  Trial of calcium to prevent preeclampsia. , 1997, The New England journal of medicine.

[47]  C. Damsky,et al.  Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? , 1997, The Journal of clinical investigation.

[48]  E. Dejana,et al.  Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? , 1997, The Journal of clinical investigation.

[49]  R. Taylor.  Review: Immunobiology of Preeclampsia , 1997, American journal of reproductive immunology.

[50]  L R Caplan,et al.  A reversible posterior leukoencephalopathy syndrome. , 1996, The New England journal of medicine.

[51]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[52]  P. Kincaid‐smith.  Hypertension in Pregnancy , 1993, Blood pressure.

[53]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[54]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[55]  J. V. van Mourik,et al.  Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. , 1992, International immunology.

[56]  Joe Leigh Simpson,et al.  Obstetrics: Normal and Problem Pregnancies , 1986 .

[57]  W. E. Nelson.  Textbook of Pediatrics , 1969 .